Company intelligence
Diamyd Medical
Developing precision medicine therapies for type 1 diabetes
About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes through innovative research and clinical development. The flagship investigational product is a precision medicine treatment under clinical evaluation, serving as a disease-modifying therapy aimed at preserving endogenous insulin production in individuals with type 1 diabetes. It is based on the autoantigen GAD65 and has received Orphan Drug Designation as well as Fast Track Designation by the U.S. FDA. Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.
Verified activity
Signals from Diamyd Medical
3 published signals
Presence & Recognition
Diamyd Medical Head of Biomanufacturing Sofia Mayans is speaking at Nordic Life Science Days on the Pharma Track on 8 September.
Reported by Diamyd Medical
Presence & Recognition
Diamyd Medical is organizing the third and last ASSET conference dedicated to precision health, early disease detection and screening on the 23rd of September.
Reported by Pedro Teixeira, PhD
Operations & Supply
Diamyd Medical has a manufacturing facility in Umeå, Northern Sweden.
Reported by Diamyd Medical